295 related articles for article (PubMed ID: 10962434)
1. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers.
Conejo JR; Kleeff J; Koliopanos A; Matsuda K; Zhu ZW; Goecke H; Bicheng N; Zimmermann A; Korc M; Friess H; Büchler MW
Int J Cancer; 2000 Oct; 88(1):12-20. PubMed ID: 10962434
[TBL] [Abstract][Full Text] [Related]
2. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
Matsuda K; Maruyama H; Guo F; Kleeff J; Itakura J; Matsumoto Y; Lander AD; Korc M
Cancer Res; 2001 Jul; 61(14):5562-9. PubMed ID: 11454708
[TBL] [Abstract][Full Text] [Related]
3. Preferential expression of cystein-rich secretory protein-3 (CRISP-3) in chronic pancreatitis.
Liao Q; Kleeff J; Xiao Y; Guweidhi A; Schambony A; Töpfer-Petersen E; Zimmermann A; Büchler MW; Friess H
Histol Histopathol; 2003 Apr; 18(2):425-33. PubMed ID: 12647793
[TBL] [Abstract][Full Text] [Related]
4. COMP is selectively up-regulated in degenerating acinar cells in chronic pancreatitis and in chronic-pancreatitis-like lesions in pancreatic cancer.
Liao Q; Kleeff J; Xiao Y; Di Cesare PE; Korc M; Zimmermann A; Büchler MW; Friess H
Scand J Gastroenterol; 2003 Feb; 38(2):207-15. PubMed ID: 12678339
[TBL] [Abstract][Full Text] [Related]
5. Syndecan-1 expression--a novel prognostic marker in pancreatic cancer.
Juuti A; Nordling S; Lundin J; Louhimo J; Haglund C
Oncology; 2005; 68(2-3):97-106. PubMed ID: 15886501
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.
Fujiya M; Watari J; Ashida T; Honda M; Tanabe H; Fujiki T; Saitoh Y; Kohgo Y
Jpn J Cancer Res; 2001 Oct; 92(10):1074-81. PubMed ID: 11676858
[TBL] [Abstract][Full Text] [Related]
7. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype.
Watari J; Saitoh Y; Fujiya M; Shibata N; Tanabe H; Inaba Y; Okamoto K; Maemoto A; Ohta T; Yasuda A; Ayabe T; Ashida T; Yokota K; Obara T; Kohgo Y
J Gastroenterol; 2004; 39(2):104-12. PubMed ID: 15069616
[TBL] [Abstract][Full Text] [Related]
8. Reduced syndecan-1 expression stimulates heparin-binding growth factor-mediated invasion in ovarian cancer cells in a urokinase-independent mechanism.
Matsuzaki H; Kobayashi H; Yagyu T; Wakahara K; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
Oncol Rep; 2005 Aug; 14(2):449-57. PubMed ID: 16012729
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of syndecan expression by osteosarcoma cell lines in response to cytokines but not osteotropic hormones.
Birch MA; Skerry TM
Bone; 1999 Jun; 24(6):571-8. PubMed ID: 10375199
[TBL] [Abstract][Full Text] [Related]
10. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
[TBL] [Abstract][Full Text] [Related]
11. KAI1 is unchanged in metastatic and nonmetastatic esophageal and gastric cancers.
Guo XZ; Friess H; Maurer C; Berberat P; Tang WH; Zimmermann A; Naef M; Graber HU; Korc M; Büchler MW
Cancer Res; 1998 Feb; 58(4):753-8. PubMed ID: 9485031
[TBL] [Abstract][Full Text] [Related]
12. Expression of oncofetal fibronectin and syndecan-1 mRNA in 18 human lung cancer cell lines.
Nanki N; Fujita J; Yang Y; Hojo S; Bandoh S; Yamaji Y; Ishida T
Tumour Biol; 2001; 22(6):390-6. PubMed ID: 11786733
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential.
Matsumoto A; Ono M; Fujimoto Y; Gallo RL; Bernfield M; Kohgo Y
Int J Cancer; 1997 Oct; 74(5):482-91. PubMed ID: 9355969
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-1 expression in locally invasive and metastatic prostate cancer.
Chen D; Adenekan B; Chen L; Vaughan ED; Gerald W; Feng Z; Knudsen BS
Urology; 2004 Feb; 63(2):402-7. PubMed ID: 14972511
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of Silencer of death domains (SODD/BAG-4) in pancreatic cancer.
Ozawa F; Friess H; Zimmermann A; Kleeff J; Büchler MW
Biochem Biophys Res Commun; 2000 May; 271(2):409-13. PubMed ID: 10799310
[TBL] [Abstract][Full Text] [Related]
16. Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract.
Kayed H; Kleeff J; Ding J; Hammer J; Giese T; Zentgraf H; Büchler MW; Friess H
Histol Histopathol; 2004 Oct; 19(4):1021-31. PubMed ID: 15375745
[TBL] [Abstract][Full Text] [Related]
17. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
18. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases.
Roskams T; Rosenbaum J; De Vos R; David G; Desmet V
Hepatology; 1996 Sep; 24(3):524-32. PubMed ID: 8781318
[TBL] [Abstract][Full Text] [Related]
19. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon.
Streppel MM; Vincent A; Mukherjee R; Campbell NR; Chen SH; Konstantopoulos K; Goggins MG; Van Seuningen I; Maitra A; Montgomery EA
Hum Pathol; 2012 Oct; 43(10):1755-63. PubMed ID: 22542127
[TBL] [Abstract][Full Text] [Related]
20. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression.
Watanabe A; Mabuchi T; Satoh E; Furuya K; Zhang L; Maeda S; Naganuma H
J Neurooncol; 2006 Mar; 77(1):25-32. PubMed ID: 16132527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
